Optimizing safety of COPD treatments: role of the nurse practitioner

References

• JemalAWardEHaoYThunMTrends in the leading causes of death in the United States, 1970–2002JAMA2005294101255125916160134
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthMorbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases Available from: http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdfAccessed July 5, 2012
   Google Scholar
• ManninoDMHomaDMAkinbamiLJFordESReddSCChronic obstructive pulmonary disease surveillance – United States, 1971–2000MMWR Surveill Summ2002516116
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated Dec 2011. Available from: http://www.goldcopd.orgAccessed July 5, 2012
   Google Scholar
• BelferMHReardonJZImproving exercise tolerance and quality of life in patients with chronic obstructive pulmonary diseaseJ Am Osteopath Assoc2009109526827819451260
   PubMedGoogle Scholar
• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599
   PubMed Web of Science ®Google Scholar
• HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J200628352353216611654
   PubMed Web of Science ®Google Scholar
• FeenstraTLvan GenugtenMLHoogenveenRTWoutersEFRutten-van MölkenMPThe impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in The NetherlandsAm J Respir Crit Care Med2001164459059611520721
   PubMed Web of Science ®Google Scholar
• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWAgustiAStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• O’DonnellDEHernandezPKaplanACanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary careCan Respir J200815 Suppl A1A8A
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEEnrightPLManfredaJHospitalizations and mortality in the Lung Health StudyAm J Respir Crit Care Med2002166333333912153966
   PubMed Web of Science ®Google Scholar
• WaltersJAWaltersEHWood-BakerROral corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20053CD00537416034972
   PubMedGoogle Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMKestenSLiuDMehraSTashkinDPMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20091801094895519729663
   PubMed Web of Science ®Google Scholar
• CelliBRThomasNEAndersonJAEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
   PubMed Web of Science ®Google Scholar
• RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulmon Dis20083337138418990964
   PubMedGoogle Scholar
• DahlRGreefhorstLANowakDInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577878411549532
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• BoydGMoriceAHPounsfordJCSiebertMPeslisNCrawfordCAn evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)Eur Respir J19971048158219150318
   PubMed Web of Science ®Google Scholar
• DonohueJFParseyMVAndrewsCEvaluation of the efficacy and safety of levalbuterol in subjects with COPDCOPD20063312513217240614
   PubMedGoogle Scholar
• RennardSIAndersonWZuWallackRUse of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116351087109211316640
   PubMed Web of Science ®Google Scholar
• BaumgartnerRAHananiaNACalhounWJSahnSASciarappaKHanrahanJPNebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trialClin Ther200729226127817472819
   PubMed Web of Science ®Google Scholar
• HanrahanJPHananiaNACalhounWJSahnSASciarappaKBaumgartnerRAEffect of nebulized arformoterol on airway function in COPD: results from two randomized trialsCOPD200851253418259972
   PubMedGoogle Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthCLanesSPooled clinical trial analysis of tiotropium safetyChest200613061695170317166984
   PubMed Web of Science ®Google Scholar
• TaylorJKotchARiceKIpratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPDChest200112041253126111591569
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBEComparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• OhtaKFukuchiYGrouseLA prospective clinical study of theophylline safety in 3810 elderly with asthma or COPDRespir Med200498101016102415481279
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• PauwelsRALöfdahlCGLaitinenLALong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med1999340251948195310379018
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLHebertPOutpatient oral prednisone after emergency treatment of chronic obstructive pulmonary diseaseN Engl J Med2003348262618262512826636
   PubMed Web of Science ®Google Scholar
• AliaIde la CalMAEstebanAEfficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory supportArch Intern Med2011171211939194622123804
   PubMedGoogle Scholar
• DaviesLAngusRMCalverleyPMOral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trialLancet1999354917745646010465169
   PubMed Web of Science ®Google Scholar
• MaltaisFOstinelliJBourbeauJComparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trialAm J Respir Crit Care Med2002165569870311874817
   PubMed Web of Science ®Google Scholar
• NiewoehnerDEErblandMLDeupreeRHEffect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study GroupN Engl J Med1999340251941194710379017
   PubMed Web of Science ®Google Scholar
• WaltersJAGibsonPGWood-BakerRHannayMWaltersEHSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseCochrane Database Syst Rev20091CD00128819160195
   PubMed Web of Science ®Google Scholar
• AbramsonMJWaltersJWaltersEHAdverse effects of beta-agonists: are they clinically relevant?Am J Respir Med20032428729714719995
   PubMedGoogle Scholar
• KellyHWRisk versus benefit considerations for the β2-agonistsPharmacotherapy2006269 Pt 2164S174S16945063
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEECardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysisChest200412562309232115189956
   PubMed Web of Science ®Google Scholar
• SuissaSAssimesTErnstPInhaled short acting β agonist use in COPD and the risk of acute myocardial infarctionThorax2003581434612511719
   PubMed Web of Science ®Google Scholar
• CampbellSCCrinerGJLevineBECardiac safety of formoterol 12 μg twice daily in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther200720557157916911869
   PubMed Web of Science ®Google Scholar
• RodrigoGJNanniniLJRodríguez-RoisinRSafety of long-acting β-agonists in stable COPD: a systematic reviewChest200813351079108718460518
   PubMed Web of Science ®Google Scholar
• FergusonGTFunck-BrentanoCFischerTDarkenPReisnerCCardiovascular safety of salmeterol in COPDChest200312361817182412796155
   PubMed Web of Science ®Google Scholar
• OgaleSSLeeTAAuDHBoudreauDMSullivanSDCardiovascular events associated with ipratropium bromide in COPDChest20101371131919363211
   PubMed Web of Science ®Google Scholar
• LeeTAPickardASAuDHBartleBWeissKBRisk for death associated with medications for recently diagnosed chronic obstructive pulmonary diseaseAnn Intern Med2008149638039018794557
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSTiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax2006611085486216844726
   PubMed Web of Science ®Google Scholar
• ObaYZazaTThameemDMSafety, tolerability and risk benefit analysis of tiotropium in COPDInt J Chron Obstruct Pulmon Dis20083457558419281075
   PubMedGoogle Scholar
• CelliBDecramerMLeimerIVogelUKestenSTashkinDPCardiovascular safety of tiotropium in patients with COPDChest20101371203019592475
   PubMed Web of Science ®Google Scholar
• Atrovent^® HFA [package insert]102011 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Atrovent+HFA/10003001_US_1.pdfAccessed July 5, 2012
   Google Scholar
• GrossNJAnticholinergic agents in asthma and COPDEur J Pharmacol20065331–3363916488410
   PubMed Web of Science ®Google Scholar
• ScullionJEThe development of anticholinergics in the management of COPDInt J Chron Obstruct Pulmon Dis200721334018044064
   PubMedGoogle Scholar
• MicheleTMPinheiroSIyasuSThe safety of tiotropium – the FDA’s conclusionsN Engl J Med2010363121097109920843240
   PubMed Web of Science ®Google Scholar
• Brovana^® [package insert]22012 Available from: http://www.brovana.com/BrovanaApprovedLabelingText.pdfAccessed July 5, 2012
   Google Scholar
• Foradil^® Aerolizer^® [package insert]32012 Available from: http://www.spfiles.com/piforadil.pdfAccessed July 5, 2012
   Google Scholar
• Serevent^® Diskus^® [package insert]12012 Available from: http://us.gsk.com/products/assets/us_serevent_diskus.pdfAccessed July 5, 2012
   Google Scholar
• NelsonHSWeissSTBleeckerERYanceySWDorinskyPMThe Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest20061291152616424409
   PubMed Web of Science ®Google Scholar
• ChowdhuryBADal PanGThe FDA and safe use of long-acting beta-agonists in the treatment of asthmaN Engl J Med2010362131169117120181964
   PubMed Web of Science ®Google Scholar
• Spiriva^® HandiHaler^® [package insert]32012 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdfAccessed July 5, 2012
   Google Scholar
• MedlinePlusTheophylline82010 Available from: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a681006.htmlAccessed July 5, 2012
   Google Scholar
• Flovent-HFA^® [package insert]12012 Available from: http://us.gsk.com/products/assets/us_flovent_hfa.pdfAccessed July 5, 2012
   Google Scholar
• Pulmicort Flexhaler^® [package insert]72010 Available from: http://www1.astrazeneca-us.com/pi/pulmicortfh.pdfAccessed July 5, 2012
   Google Scholar
• GartlehnerGHansenRACarsonSSLohrKNEfficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomesAnn Fam Med20064325326216735528
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• DrummondMBDasenbrookECPitzMWMurphyDJFanEInhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300202407241619033591
   PubMed Web of Science ®Google Scholar
• Lung Health Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med2000343261902190911136260
   PubMed Web of Science ®Google Scholar
• HubbardRBSmithCJSmeethLHarrisonTWTattersfieldAEInhaled corticosteroids and hip fracture: a population-based case-control studyAm J Respir Crit Care Med200216612 Pt 11563156612406825
   PubMed Web of Science ®Google Scholar
• LeeTAWeissKBFracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2004169785585914711795
   PubMed Web of Science ®Google Scholar
• JohnellOPauwelsRLöfdahlCGBone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide TurbuhalerEur Respir J20021961058106312108857
   PubMed Web of Science ®Google Scholar
• FergusonGTCalverleyPMAndersonJAPrevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health studyChest200913661456146519581353
   PubMed Web of Science ®Google Scholar
• LanghammerAForsmoSSyversenULong-term therapy in COPD: any evidence of adverse effect on bone?Int J Chron Obstruct Pulmon Dis2009436538019888355
   PubMedGoogle Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• Combivent^® [package insert]92011 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+IA/combivent.pdfAccessed July 5, 2012
   Google Scholar
• Advair^® Diskus^® [package insert]92011 Available from: http://us.gsk.com/products/assets/us_advair.pdfAccessed July 5, 2012
   Google Scholar
• Symbicort^® [package insert]62010 Available from: http://www1.astrazeneca-us.com/pi/symbicort.pdfAccessed July 5, 2012
   Google Scholar
• MoorePLPractice management and chronic obstructive pulmonary disease in primary careAm J Med20071208 Suppl 1S23S2717678940
   PubMed Web of Science ®Google Scholar
• BarrRGCelliBRManninoDMComorbidities, patient knowledge, and disease management in a national sample of patients with COPDAm J Med2009122434835519332230
   PubMed Web of Science ®Google Scholar
• NelsonMHamiltonHEImproving in-office discussion of chronic obstructive pulmonary disease: results and recommendations from an in-office linguistic study in chronic obstructive pulmonary diseaseAm J Med20071208 Suppl 1S28S3217678941
   PubMed Web of Science ®Google Scholar
• CramerJABradley-KennedyCScaleraATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J2007141252917315055
   PubMed Web of Science ®Google Scholar
• LaforestLDenisFVan GanseECorrelates of adherence to respiratory drugs in COPD patientsPrim Care Respir J201019214815420094689
   PubMedGoogle Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar